Roivant Sciences is trading 15.41% down at $34.53, with the after-hours reversal remaining unexplained.

  • Closed at $40.82 on September 11, 2026.
  • No reliable September 11 company-specific announcement or late-breaking catalyst was identified.
  • Recent coverage highlighted positive September 8 mosliciguat Phase 2 results and subsequent analyst target increases, while the broader market was generally stronger on September 11.